The analysis of Reactome, KEGG and GO showed that miRNAs down-regulated in the stable CAD patients compared to the control individuals could regulate insulin resistance, insulin signalling, sphingolipid signalling and non-alcoholic fatty liver disease (NAFLD) pathways. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.